share_log

BG Medicine (OTCMKTS:BGMD) Vs. Lucira Health (NASDAQ:LHDX) Head to Head Contrast

BG Medicine (OTCMKTS:BGMD) Vs. Lucira Health (NASDAQ:LHDX) Head to Head Contrast

BG Medicine(OTCMKTS: BGMD)vs.Lucira Health(纳斯达克股票代码:LHDX)头对头对比
Financial News Live ·  2023/03/07 17:43

BG Medicine (OTCMKTS:BGMD – Get Rating) and Lucira Health (NASDAQ:LHDX – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

BG Medicine(OTCMKTS: BGMD — 获取评级)和 Lucira Health(纳斯达克股票代码:LHDX — 获取评级)都是医疗公司,但哪家业务更好?我们将根据两家公司的股息、盈利能力、估值、机构所有权、风险、收益和分析师建议对两家公司进行比较。

Insider & Institutional Ownership

内部所有权和机构所有权

57.0% of Lucira Health shares are held by institutional investors. 6.5% of BG Medicine shares are held by company insiders. Comparatively, 30.4% of Lucira Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lucira Health的57.0%股份由机构投资者持有。6.5%的BG Medicine股份由公司内部人士持有。相比之下,Lucira Health的30.4%股份由公司内部人士持有。强大的机构所有权表明,捐赠基金、对冲基金和大型基金经理认为,从长远来看,股票的表现将超过市场。

Get
获取
BG Medicine
BG 医学
alerts:
警报:

Profitability

盈利能力

This table compares BG Medicine and Lucira Health's net margins, return on equity and return on assets.

该表比较了BG Medicine和Lucira Health的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
BG Medicine N/A N/A N/A
Lucira Health -67.54% -13.55% -8.47%
净利润 股本回报率 资产回报率
BG 医学 不适用 不适用 不适用
露西拉健康 -67.54% -13.55% -8.47%

Analyst Recommendations

分析师建议

This is a summary of recent ratings and recommmendations for BG Medicine and Lucira Health, as reported by MarketBeat.

据MarketBeat报道,这是BG Medicine和Lucira Health的最新评级和建议摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BG Medicine 0 0 0 0 N/A
Lucira Health 0 0 1 0 3.00
卖出评级 保持收视率 买入评级 强劲的买入评级 评分分数
BG 医学 0 0 0 0 不适用
露西拉健康 0 0 1 0 3.00

Risk and Volatility

风险和波动性

BG Medicine has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Lucira Health has a beta of 3.75, suggesting that its share price is 275% more volatile than the S&P 500.

BG Medicine的beta值为0.28,这表明其股价的波动性比标准普尔500指数低72%。相比之下,Lucira Health的beta值为3.75,这表明其股价的波动性比标准普尔500指数高275%。

Earnings & Valuation

收益与估值

This table compares BG Medicine and Lucira Health's revenue, earnings per share and valuation.

该表比较了BG Medicine和Lucira Health的收入、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BG Medicine N/A N/A N/A N/A N/A
Lucira Health $93.06 million 0.19 -$64.83 million ($3.58) -0.13
总收入 价格/销售比率 净收入 每股收益 市盈率
BG 医学 不适用 不适用 不适用 不适用 不适用
露西拉健康 9306 万美元 0.19 -6,483 万美元 (3.58 美元) -0.13

BG Medicine has higher earnings, but lower revenue than Lucira Health.

与Lucira Health相比,BG Medicine的收益更高,但收入更低。

Summary

摘要

Lucira Health beats BG Medicine on 5 of the 8 factors compared between the two stocks.

与两只股票相比,Lucira Health在8个因素中的5个因素上击败了BG Medicine。

About BG Medicine

关于 BG 医学

(Get Rating)

(获取评分)

BG Medicine, Inc. is a life sciences company. It engages in developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The firm distributes products such as BGM Galectin-3 to clinical laboratories, hospitals, and healthcare providers. The company was founded in February 2000 by Jan van der Greef and is headquartered in Foxboro, MA.

BG Medicine, Inc. 是一家生命科学公司。它致力于为医疗保健提供者开发和提供创新解决方案,这些解决方案提供见解并改变心力衰竭和相关疾病的临床护理。该公司向临床实验室、医院和医疗保健提供者分销BGM Galectin-3等产品。该公司由扬·范德格里夫于2000年2月创立,总部位于马萨诸塞州福克斯伯勒。

About Lucira Health

关于 Lucira Health

(Get Rating)

(获取评分)

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

Lucira Health, Inc. 是一家医疗技术公司,专注于传染病检测试剂盒的开发和商业化。它开发了一个提供分子测试服务的测试平台。该公司提供 LUCIRA COVID-19 多合一测试套件,一个 COVID-19 测试套件;并开发甲型和乙型流感病毒测试套件。它与Eiken化学株式会社签订了专利许可协议;与Jabil, Inc.签订了技术服务协议;与Jabil MSA签订了制造服务协议。该公司前身为DiAssess Inc.,并于2020年1月更名为Lucira Health, Inc.Lucira Health, Inc. 成立于 2013 年,总部位于加利福尼亚州埃默里维尔。

Receive News & Ratings for BG Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

接收 BG 医学日报的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收BG Medicine及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发